drugset / Trial / NCT02099838
Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients
Phase 4
Completed
98 enrolled
Huazhong University of Science and Technology
Hubei Xinhua Hospital · collabWuhan Iron and Steel Workers' Hospital · collabWuhan Pu-Ai Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic patients after treatment with SUs for 5 years, although SUs are widely used in type 2 diabetic patients. This study was designed to evaluate the effectiveness and safety of adding compound preparation of pioglitazone and metformin for type 2 diabetic patients who have bad glycemic control with the initial treatment of SUs.
Timeline
- Start
- 2012-01
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | Oral |
| Subject | Pioglitazone | Small molecule | 2 mg | Oral |